George Rodrigues1, Xiaomei Yao2, D Andrew Loblaw3, Michael Brundage4, Joseph L Chin5. 1. London Health Sciences Centre, Department of Oncology, Western University, London, ON; 2. Program in Evidence-based Care, McMaster University, Hamilton, ON; 3. Department of Radiation Oncology, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, ON; 4. Division of Cancer Care and Epidemiology, Cancer Research Institute, Queen's University; 5. Division of Urology, London Health Sciences Centre, Division of Surgical Oncology, Schulich School of Medicine and Dentistry, Western University, London, ON.
Abstract
INTRODUCTION: We review the current evidence for the role of low-dose rate brachytherapy (PB) in patients with low- or intermediate-risk prostate cancer using a systematic review of the literature. METHODS: We searched MEDLINE and EMBASE (from January 1996 to October 2011), the Cochrane Library, relevant guideline web-sites, and websites for meetings specific for genitourinary diseases. RESULTS: Ten systematic reviews and 55 single-study papers met the pre-planned study selection criteria. In the end, 36 articles were abstracted and analyzed for this systematic review. There is no evidence for a difference in efficacy between PB and external beam radiation therapy (EBRT), or between PB and radical prostatectomy (RP). During the 6 months to 3 years after treatment, PB was associated with less urinary incontinence and sexual impotency than RP, and RP was associated with less urinary irritation and rectal morbidity than PB. However, these differences diminished over time. PB conferred less risk of impotency and rectal morbidity in the three years after treatment than EBRT. Iodine-125 and alladium-103 did not differ with respect to biochemical relapse-free survival and patient-reported outcomes. CONCLUSIONS: PB alone is a treatment option with equal efficacy to EBRT or RP alone in patients with newly diagnosed low- or intermediate-risk prostate cancer who require or choose active treatment.
INTRODUCTION: We review the current evidence for the role of low-dose rate brachytherapy (PB) in patients with low- or intermediate-risk prostate cancer using a systematic review of the literature. METHODS: We searched MEDLINE and EMBASE (from January 1996 to October 2011), the Cochrane Library, relevant guideline web-sites, and websites for meetings specific for genitourinary diseases. RESULTS: Ten systematic reviews and 55 single-study papers met the pre-planned study selection criteria. In the end, 36 articles were abstracted and analyzed for this systematic review. There is no evidence for a difference in efficacy between PB and external beam radiation therapy (EBRT), or between PB and radical prostatectomy (RP). During the 6 months to 3 years after treatment, PB was associated with less urinary incontinence and sexual impotency than RP, and RP was associated with less urinary irritation and rectal morbidity than PB. However, these differences diminished over time. PB conferred less risk of impotency and rectal morbidity in the three years after treatment than EBRT. Iodine-125 and alladium-103 did not differ with respect to biochemical relapse-free survival and patient-reported outcomes. CONCLUSIONS:PB alone is a treatment option with equal efficacy to EBRT or RP alone in patients with newly diagnosed low- or intermediate-risk prostate cancer who require or choose active treatment.
Authors: Andrew Herstein; Kent Wallner; Gregory Merrick; Hiroki Mitsuyama; Julius Armstrong; Lawrence True; William Cavanagh; Wayne Butler Journal: Cancer J Date: 2005 Sep-Oct Impact factor: 3.360
Authors: Douglas W Soderdahl; John W Davis; Paul F Schellhammer; Robert W Given; Donald F Lynch; Mark Shaves; Bonnie L Burke; Michael D Fabrizio Journal: J Endourol Date: 2005-04 Impact factor: 2.942
Authors: Joycelyn L Speight; Eric P Elkin; David J Pasta; Stefanie Silva; Deborah P Lubeck; Peter R Carroll; Mark S Litwin Journal: Int J Radiat Oncol Biol Phys Date: 2004-11-15 Impact factor: 7.038
Authors: Jerrold Sharkey; Alan Cantor; Zucel Solc; William Huff; Stanley D Chovnick; Raymond J Behar; Ramon Perez; Juan Otheguy; Richard Rabinowitz Journal: Curr Urol Rep Date: 2002-06 Impact factor: 3.092
Authors: Leslie R Schover; Rachel T Fouladi; Carla L Warneke; Leah Neese; Eric A Klein; Craig Zippe; Patrick A Kupelian Journal: Cancer Date: 2002-10-15 Impact factor: 6.860
Authors: Patrick A Kupelian; Louis Potters; Deepak Khuntia; Jay P Ciezki; Chandana A Reddy; Alwyn M Reuther; Thomas P Carlson; Eric A Klein Journal: Int J Radiat Oncol Biol Phys Date: 2004-01-01 Impact factor: 7.038
Authors: Vonetta M Williams; Jenna M Kahn; Nikhil G Thaker; Sushil Beriwal; Paul L Nguyen; Douglas Arthur; Daniel Petereit; Brandon A Dyer Journal: Adv Radiat Oncol Date: 2020-11-06